We can’t show the full text here under this license. Use the link below to read it at the source.
PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice
Real-World Use of Oral Semaglutide in Swedish Adults with Type 2 Diabetes
AI simplified
Abstract
A total of 187 participants achieved a mean glycated hemoglobin reduction of 0.88% after 34-44 weeks of once-daily oral semaglutide.
- Mean baseline glycated hemoglobin was 7.8%, and baseline body weight was 96.9 kg.
- At the end of the study, 64.6% of participants had glycated hemoglobin levels below 7%.
- Participants experienced a mean body weight reduction of -4.72%.
- 22.9% of participants achieved both a glycated hemoglobin reduction of at least 1% and a body weight reduction of at least 5%.
- Treatment satisfaction improved, with an average increase of 12.3 points on the Diabetes Treatment Satisfaction Questionnaire.
- Gastrointestinal disorders were the most common adverse events, with serious adverse events occurring in 4.8% of participants.
AI simplified
Key numbers
-0.88%-points
Decrease in HbA
Change from baseline to end of study
-4.72%
Decrease in Body Weight
Change from baseline to end of study
64.6%
Proportion Achieving HbA < 7%
Participants achieving target by end of study